OR WAIT null SECS
September 16, 2026
Article
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
September 15, 2026
Jim Blando, PhD, of Old Dominion University, explains why allergic patients' lung function dropped most 1 year after wildfire smoke exposure.
September 14, 2026
New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.
September 12, 2026
As ragweed and mold drive this year's fall symptom surge, updated GRADE recommendations shift first-line therapy toward combination intranasal treatment.
September 01, 2026
FDA actions, a WAO consensus update, and late-stage trial data in food allergy, anaphylaxis, CRSwNP, and EoE, all in this August 2026 recap.
August 20, 2026
The generic nasal spray is bioequivalent to Haleon's Flonase, indicated for nasal symptoms of allergic rhinitis.
July 21, 2026
FDA expands RYALTRIS® approval to children aged 6 to 11 with seasonal allergic rhinitis, based on phase 3 trial data.
July 15, 2026
Video
Preliminary real-world data presented at EAACI 2026 found broad reductions in respiratory tract infections with OM-85, David Price, MD, said.
April 02, 2026
March 2026 allergy news: FDA label updates, mastocytosis NDA, and promising data for peanut patch, remibrutinib, and CRSwNP biologics.
April 01, 2026
A study shows that weekly or daily throat clearing, hoarseness, and voice strain are more common among those with diagnosed respiratory allergies, particularly among women.
